Originator: Calithera Biosciences
Buyer: Incyte
Upfront payment: $45m
Estimated value: ~$500m
Target molecule: Arginase
Target cell: MDSC
Clinical setting: Combination with anti-PD-1 ab
Current stage: P1
Another Arginase inhibitors:
Target evaluation: fast-follow 가능?
http://www.calithera.com/wp-content/uploads/2016/01/Keystone-immunotherapy-2016-poster.final_.pdf
광고